I am/have/had
I am looking for
Advanced Filters
Found 2 clinical trials
Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
The primary objective of the trial is to evaluate the antitumor activity of atezolizumab and rucaparib in patients with selected advanced solid tumors as measured by the Overall Response Rate
international normalized ratio
oophorectomy
solid tumour
hormonal contraception
fine needle aspiration
- 0 views
- 19 Feb, 2024
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Patients will be treated with the combination of copanlisib and rucaparib for as long as the patient does not have clinically significant progressive disease and/or unacceptable toxicity and/or as long as the investigator deems that the patient is benefiting from treatment.
glycosylated hemoglobin
gnrh
ppp2r2a
copanlisib
carcinoma
- 0 views
- 19 Feb, 2024